Pharma Company Seeks an Out-License and Investors

The company a specialty pharmaceutical company advancing a late-stage portfolio of value-added CNS products, partnered and developed in collaboration with leading European pharmaceutical companies. They are now seeking strategic partnerships with North American companies specializing in the marketing of specialty psychiatry medicines. Additionally, the company is raising 10 million USD to support the global launch of its portfolio, which includes six products—most of which have been fully funded through non-dilutive strategic investments.

The portfolio consists of 505(b)(2) formulations targeting depression and ADHD. These products leverage the company's patented oral drug delivery platform, which enables breakable modified-release formulations with significant benefits. These include reduced side effects, unique dosing strengths, and flexible titration for maintaining premium pricing over generics. With 505(b)(2) pathway approval (without the need for large clinical efficacy studies) and strong patent protection until 2038, the company is well-positioned for success with royalty commitments of greater than 100 million USD already secured. The portfolio is late stage with the lead product validated by US-based commercial companies. The management team includes experienced pharmaceutical executives and key opinion leaders (KOLs) who bring a wealth of expertise to the table.